BIOADAPTIVES, INC.
For the period ended Dec 31, 2025. Filed Apr 14, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 14, 2026
BDPTStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOW
| Years ended | ||||
|---|---|---|---|---|
| December 31, | ||||
| 2025 · 2024 | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||
| Net loss | $(1,557,898) | $(899,161) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Change in fair value of derivative liabilities | 578,645 | 210,043 | ||
| Bad debt | 2,859 | - | ||
| Impairment of patent | - | 18,000 | ||
| Impairment of inventory | - | 81,350 | ||
| Amortization of license and patent | - | 1,941 | ||
| Amortization of debt discount | 25,132 | 52,592 | ||
| Management compensation | 443,670 | 208,871 | ||
| Depreciation | 4,000 | - | ||
| Gain on settlement of debt | (133,800) | - | ||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | (59) | - | ||
| Inventory | (25,591) | (25,184) | ||
| Prepaid expense | 93,750 | 57,200 | ||
| Accounts payable and accrued liabilities | 53,267 | 44,831 | ||
| Net Cash Used in Operating Activities | (516,025) | (249,517) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||
| Purchase property and equipment's | (18,000) | - | ||
| Net Cash Used in Investing Activities | (18,000) | - | ||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||
| Proceeds from issuance of Series D Preferred Stock | 300,000 | 294,115 | ||
| Proceeds from notes payable | - | 32,096 | ||
| Proceeds from convertible notes | 255,000 | - | ||
| Net Cash Provided by Financing Activities | 555,000 | 326,211 | ||
| Net change in cash | 20,975 | 76,694 | ||
| Cash at beginning of period | 137,470 | 60,776 | ||
| Cash at end of period | $158,445 | $137,470 | ||
| SUPPLEMENTAL CASH FLOW INFORMATION: | ||||
| Cash paid for income taxes | $ | - | $ | - |
| Cash paid for interest | $ | - | $ | - |
| NON-CASH INVESTING AND FINANCING ACTIVITIES | ||||
| Derivative liability recognized as debt discount | $255,000 | $ | - | |
| Issuance of common stock for conversion of debt | $148,090 | $202,643 | ||
| Issuance of common stock for conversion of debt | $150,000 | $ | - | |
| Issuance of Series A preferred stock for license fee | $ | - | $1,500 | |
| Issuance of Series B preferred stock for license fee | $ | - | $3,000 | |
| Issuance of Series B preferred stock for settlement of debt - related party | $ | - | $1,500 | |
| Issuance of Series C preferred stock for purchase of inventory | $ | - | $60,000 | |
| Convertible note issued for consulting service | $ | - | $150,000 | |
| Debt forgiveness | $ | - | $310,245 | |
F- 6
Table of Contents
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.